Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 467

1.

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA.

Mol Ther. 2001 Sep;4(3):201-10.

2.
3.
4.
5.

Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW.

Gene Ther. 2005 Oct;12(19):1453-64.

PMID:
15889137
6.

Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.

High KA.

Trans Am Clin Climatol Assoc. 2003;114:337-51; discussion 351-2. Review.

7.

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA.

Mol Ther. 2000 Mar;1(3):225-35.

8.

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B.

Blood. 2003 Apr 15;101(8):2963-72. Epub 2002 Dec 19.

9.

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.

Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA.

Nat Genet. 1997 Jul;16(3):270-6.

PMID:
9207793
10.

AAV-mediated gene transfer for hemophilia.

High KA.

Ann N Y Acad Sci. 2001 Dec;953:64-74. Review.

PMID:
11795424
11.

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA.

Nat Genet. 2000 Mar;24(3):257-61.

PMID:
10700178
12.

Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.

Schneider H, Mühle C, Douar AM, Waddington S, Jiang QJ, von der Mark K, Coutelle C, Rascher W.

J Gene Med. 2002 Jan-Feb;4(1):46-53.

PMID:
11828387
13.

Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

Fabb SA, Dickson JG.

Curr Opin Mol Ther. 2000 Oct;2(5):601-6. Review.

PMID:
11249763
14.

Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.

Sabatino DE, Mackenzie TC, Peranteau W, Edmonson S, Campagnoli C, Liu YL, Flake AW, High KA.

Mol Ther. 2007 Sep;15(9):1677-85. Epub 2007 Jun 12.

PMID:
17565352
15.

Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.

Cao O, Armstrong E, Schlachterman A, Wang L, Okita DK, Conti-Fine B, High KA, Herzog RW.

Blood. 2006 Jul 15;108(2):480-6. Epub 2006 Mar 16.

16.

Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.

Larson PJ, High KA.

Adv Exp Med Biol. 2001;489:45-57. Review. No abstract available.

PMID:
11554590
17.

Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW.

Hum Gene Ther. 2009 Jul;20(7):767-76. doi: 10.1089/hum.2008.161.

18.

AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.

Hasbrouck NC, High KA.

Gene Ther. 2008 Jun;15(11):870-5. doi: 10.1038/gt.2008.71. Epub 2008 Apr 24. Review.

PMID:
18432276
19.

Persistent expression of canine factor IX in hemophilia B canines.

Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C.

Gene Ther. 1999 Oct;6(10):1695-704.

20.

Adeno-associated virus-mediated gene transfer for hemophilia B.

High KA.

Int J Hematol. 2002 Nov;76(4):310-8. Review.

PMID:
12463593
Items per page

Supplemental Content

Write to the Help Desk